Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Insider & Institutional Ownership
77.7% of Taysha Gene Therapies shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Artiva Biotherapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Artiva Biotherapeutics | N/A | N/A | -$83.86 million | ($3.30) | -2.06 |
| Taysha Gene Therapies | $9.77 million | 147.74 | -$109.00 million | ($0.42) | -10.55 |
Artiva Biotherapeutics has higher earnings, but lower revenue than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Artiva Biotherapeutics and Taysha Gene Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Artiva Biotherapeutics | N/A | -53.86% | -48.16% |
| Taysha Gene Therapies | N/A | -56.19% | -41.84% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Artiva Biotherapeutics and Taysha Gene Therapies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Artiva Biotherapeutics | 1 | 0 | 4 | 1 | 2.83 |
| Taysha Gene Therapies | 1 | 0 | 12 | 2 | 3.00 |
Artiva Biotherapeutics presently has a consensus target price of $39.00, indicating a potential upside of 473.53%. Taysha Gene Therapies has a consensus target price of $12.77, indicating a potential upside of 188.24%. Given Artiva Biotherapeutics’ higher probable upside, research analysts plainly believe Artiva Biotherapeutics is more favorable than Taysha Gene Therapies.
Summary
Taysha Gene Therapies beats Artiva Biotherapeutics on 8 of the 13 factors compared between the two stocks.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
